Skip to main content

Table 3 AD neuropahological changes in sCJD and gCJD

From: The characterization of AD/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded Aβ and prion proteins

  sCJD gCJDa p sCJDMM(V)1 V210I p E200Kb pc
ABC score
 Not 144 (37.3) 29 (45.3) 0.481 93 (34.4) 9 (30.0) 0.747 11 (55.0) 0.170
 Low 210 (54.4) 30 (46.9) 152 (56.3) 17 (56.7) 8 (40.0)
 Intermediate/High 32 (8.3) 5 (7.8) 25 (9.3) 4 (13.3) 1 (5.0)
Thal score
 0 144 (37.3) 29 (45.3) 0.577 93 (34.4) 9 (30.0) 0.835 11 (55.0) 0.256
 1–2 118 (30.6) 15 (23.4) 84 (31.1) 8 (26.7) 4 (20.0)
 3 76 (19.7) 13 (20.3) 56 (20.7) 8 (26.7) 4 (20.0)
 4–5 48 (12.4) 7 (10.9) 37 (13.7) 5 (16.7) 1 (5.0)
CAA
 Not CAA 275 (71.2) 47 (73.4) 0.422 187 (69.3) 22 (73.3) 0.409 15 (75.0) 0.398
 CAA 111 (28.8) 17 (26.6) 83 (30.7) 8 (26.7) 5 (25.0)
Braak score
 0 − + 208 (53.9) 34 (53.1) 0.562 133 (49.3) 11 (36.7) 0.377 13 (65.0) 0.328
 I-II 133 (34.5) 25 (39.1) 102 (37.8) 15 (50.0) 6 (30.0)
 > III 45 (11.7) 5 (7.8) 35 (13.0) 4 (13.3) 1 (5.0)
 n 386 64 270 30 20
Age at death (years) 68.6 ± 8.9 65.0 ± 9.4 69.6 ± 8.3 65.9 ± 8.6 63.0 ± 9.1
  1. aGenetic CJD cases include the following mutations: 30 V210I, 22 E200K, 4 R208H, 2 E219K, 2 V203I, 2 INS (4 repeats), 1 INS (5 repeats), 1 D178N
  2. bTwo gCJDE200K-129 V showing PrPSc type 2 were excluded
  3. cPearson’s chi-square test was performed in comparison to sCJDMM(V)1 group